Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals
Genhouse Bio (Suzhou) Co., Ltd. (invested in and incubated by Viva Biotech) announced that China’s...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity